Antisense drug discovery platform operator Ionis Pharmaceuticals Inc. said June 29 that it has entered its second collaboration with Biogen Inc. this year, a deal to develop a therapy for degenerative muscle disorder myotonic dystrophy type 1.
Biogen Idec To Collaborate With Isis On Treatment For Degenerative Muscle Disorder
The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.